The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis

Authors:

Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2): 73‑77

DOI: 10.17116/jnevro202212207273

Read: 2740 times

Download PDF (RU)
Contact the author
Table of contents

COMMENTS ON THE GLIMPSE STUDY ON EVALUATING THE EFFICACY OF THE DRUG CLADRIBINE IN TABLETS IN ROUTINE CLINICAL PRACTICE IN COMPARISON WITH OTHER TABLET DRUGS FOR THE PATHOGENETIC TREATMENT OF MULTIPLE SCLEROSIS
COMMENTS ON THE GLIMPSE STUDY ON EVALUATING THE EFFICACY OF THE DRUG CLADRIBINE IN TABLETS IN ROUTINE CLINICAL PRACTICE IN COMPARISON WITH OTHER TABLET DRUGS FOR THE PATHOGENETIC TREATMENT OF MULTIPLE SCLEROSIS

To cite this article:

Boyko AN. Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(7‑2):73‑77. (In Russ.)
https://doi.org/10.17116/jnevro202212207273

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Pharmacoepidemiological study of oxaliplatin safety (analysis of Russian spontaneous repo­rting data­base). Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):76-83
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Characteristics, treatment features and in-hospital mortality of patients with myocardial infa­rction over 75 years old in Russia acco­rding to the REGION-IM regi­stry. Russian Cardiology Bulletin. 2025;(1):22-38
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Postoperative peri­tonitis: epidemiology, diagnosis, surgical treatment and prognosis. Piro­gov Russian Journal of Surgery. 2025;(6):104-111
Abstract:

This study analyzes data from the open clinical trial GLIMPSE comparing the efficacy of cladribine in tablets (n=633) in comparison with fingolimod (n=1195), dimethyl fumarate (n=912), and teriflunomide (n=735) in remitting multiple sclerosis (MS) in real clinical practice. Cladribine tablets have demonstrated significantly higher efficacy compared to fingolimod, teriflunomides and dimethyl fumarate. This indicates the need for more active use of cladribine in tablets with active forms of MS.

Keywords:

multiple sclerosis
treatment
cladribine tablets
real clinical practice

Authors:

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency

Received:

31.05.2022

Accepted:

02.06.2022

Close metadata

References:

  1. Dobson R, Giovannoni G. Multiple sclerosis. Eur J Neurology. 2019;26(1):27-40. 
  2. Gusev EI, Boyko AN. Multiple sclerosis. Zdorovie Cheloveka. 2021;1:97-113. (In Russ.).
  3. Giovannoni G, Comi G, Cook S, et al. CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. NEJM. 2010;362(5):416-426. 
  4. Deeks ED. Cladribine Tablets: A Review in Relapsing MS. CNS Drugs. 2018;32(8):785-796.  https://doi.org/10.1007/s40263-018-0562-0
  5. Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscipl Healthcare. 2018;11:295-300. 
  6. Butzkueven H, Spelman T, Ozakbas S, et al. and MSBase Study Group. Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry. AAN. 2022;P12-4.003. 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.